Dudediligence.

Cardiff Oncology, Inc

CRDFNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$165,000Sep ’24$151,000Dec ’24$109,000Mar ’25$121,000Jun ’25$120,000Sep ’25$243,000Dec ’25$41,000Mar ’26$104,000Jun ’26
Net income, by quarter
−$11.9MSep ’24−$11.8MDec ’24−$13.4MMar ’25−$13.9MJun ’25−$11.3MSep ’25−$7.2MDec ’25−$12.3MMar ’26−$9.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$359,000$386,000$488,000$683,000$593,000
Operating income−$28.9M−$39.9M−$45.4M−$48.7M−$49.0M
Net income−$28.3M−$38.7M−$41.4M−$45.4M−$45.9M
Operating cash flow−$23.0M−$33.8M−$30.9M−$37.7M−$37.9M
Free cash flow−$23.2M−$34.8M−$31.5M−$37.8M−$38.0M
Cash$11.9M$16.3M$21.7M$51.5M$17.5M
Shares outstanding42.0M44.7M44.7M66.5M68.3M